QQQ   295.58 (+0.76%)
AAPL   146.07 (+1.47%)
MSFT   248.30 (+0.12%)
META   151.44 (+2.81%)
GOOGL   99.43 (+1.96%)
AMZN   102.04 (+2.84%)
TSLA   174.14 (+8.65%)
NVDA   200.79 (+1.40%)
NIO   12.32 (+1.23%)
BABA   117.46 (-2.58%)
AMD   75.72 (+0.75%)
T   19.94 (-0.30%)
MU   63.15 (+0.56%)
F   13.11 (+1.47%)
CGC   2.86 (+3.62%)
GE   83.48 (+2.88%)
DIS   109.95 (+0.23%)
AMC   5.15 (-2.46%)
PFE   44.15 (-0.23%)
PYPL   81.67 (+1.06%)
NFLX   363.41 (-0.40%)
QQQ   295.58 (+0.76%)
AAPL   146.07 (+1.47%)
MSFT   248.30 (+0.12%)
META   151.44 (+2.81%)
GOOGL   99.43 (+1.96%)
AMZN   102.04 (+2.84%)
TSLA   174.14 (+8.65%)
NVDA   200.79 (+1.40%)
NIO   12.32 (+1.23%)
BABA   117.46 (-2.58%)
AMD   75.72 (+0.75%)
T   19.94 (-0.30%)
MU   63.15 (+0.56%)
F   13.11 (+1.47%)
CGC   2.86 (+3.62%)
GE   83.48 (+2.88%)
DIS   109.95 (+0.23%)
AMC   5.15 (-2.46%)
PFE   44.15 (-0.23%)
PYPL   81.67 (+1.06%)
NFLX   363.41 (-0.40%)
QQQ   295.58 (+0.76%)
AAPL   146.07 (+1.47%)
MSFT   248.30 (+0.12%)
META   151.44 (+2.81%)
GOOGL   99.43 (+1.96%)
AMZN   102.04 (+2.84%)
TSLA   174.14 (+8.65%)
NVDA   200.79 (+1.40%)
NIO   12.32 (+1.23%)
BABA   117.46 (-2.58%)
AMD   75.72 (+0.75%)
T   19.94 (-0.30%)
MU   63.15 (+0.56%)
F   13.11 (+1.47%)
CGC   2.86 (+3.62%)
GE   83.48 (+2.88%)
DIS   109.95 (+0.23%)
AMC   5.15 (-2.46%)
PFE   44.15 (-0.23%)
PYPL   81.67 (+1.06%)
NFLX   363.41 (-0.40%)
QQQ   295.58 (+0.76%)
AAPL   146.07 (+1.47%)
MSFT   248.30 (+0.12%)
META   151.44 (+2.81%)
GOOGL   99.43 (+1.96%)
AMZN   102.04 (+2.84%)
TSLA   174.14 (+8.65%)
NVDA   200.79 (+1.40%)
NIO   12.32 (+1.23%)
BABA   117.46 (-2.58%)
AMD   75.72 (+0.75%)
T   19.94 (-0.30%)
MU   63.15 (+0.56%)
F   13.11 (+1.47%)
CGC   2.86 (+3.62%)
GE   83.48 (+2.88%)
DIS   109.95 (+0.23%)
AMC   5.15 (-2.46%)
PFE   44.15 (-0.23%)
PYPL   81.67 (+1.06%)
NFLX   363.41 (-0.40%)
NASDAQ:MDRX

Veradigm - MDRX Stock Forecast, Price & News

$17.87
-0.20 (-1.11%)
(As of 01/27/2023 12:07 PM ET)
Add
Compare
Today's Range
$17.86
$18.13
50-Day Range
$17.05
$19.59
52-Week Range
$13.59
$23.25
Volume
339,027 shs
Average Volume
1.25 million shs
Market Capitalization
$1.95 billion
P/E Ratio
41.56
Dividend Yield
N/A
Price Target
$22.67

Veradigm MarketRank™ Forecast

Analyst Rating
Moderate Buy
2.57 Rating Score
Upside/​Downside
25.4% Upside
$22.67 Price Target
Short Interest
Bearish
10.13% of Float Sold Short
Dividend Strength
N/A
Sustainability
-0.62
Upright™ Environmental Score
News Sentiment
0.64mentions of Veradigm in the last 14 days
Based on 6 Articles This Week
Insider Trading
Selling Shares
$1.14 M Sold Last Quarter
Proj. Earnings Growth
9.09%
From $0.66 to $0.72 Per Share

Overall MarketRank

MarketRank is calculated as an average of available category scores, with extra weight given to analysis and valuation.

2.56 out of 5 stars

Business Services Sector

62nd out of 329 stocks

Computer Integrated Systems Design Industry

5th out of 39 stocks


MDRX stock logo

About Veradigm (NASDAQ:MDRX) Stock

Allscripts Healthcare Solutions, Inc., together with its subsidiaries, provides information technology solutions and services to healthcare organizations in the United States, Canada, and internationally. It offers electronic health records (EHR), information connectivity, private cloud hosting, outsourcing, analytics, patient access, and population health management solutions. The company operates through two segments, Hospitals and Large Physician Practices, and Veradigm. The Hospitals and Large Physician Practices segment provides integrated clinical and financial management solutions, which primarily include EHR-related software; and related installation, support and maintenance, outsourcing, private cloud hosting, and revenue cycle management services. The Veradigm segment offers payer and life sciences solutions, which are primarily targeted at payers, life sciences companies, and other healthcare stakeholders; and software applications for patient engagement and EHR software to single-specialty, and small and mid-sized physician practices, including related clinical, financial, administrative, and operational solutions. Its solutions enable clients to transition, analyze, and coordinate care, and enhance the healthcare delivery across the care community. The company serves physicians, hospitals, governments and militaries, health systems, health plans, life-sciences companies, retail clinics, surgery centers, retail pharmacies, pharmacy benefit managers, insurance companies, employer wellness clinics, consumers, lab companies, urgent care facilities, and venture capital firms, as well as post-acute organizations, such as home health and hospice agencies. Allscripts Healthcare Solutions, Inc. was founded in 1986 and is headquartered in Chicago, Illinois.

Receive MDRX Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Veradigm and its competitors with MarketBeat's FREE daily newsletter.

MDRX Stock News Headlines

Veradigm (NASDAQ:MDRX) Sees Strong Trading Volume
Is This The End of Capitalism?
EXPOSED: The establishment plot to disenfranchise and impoverish millions of Americans…
Veradigm Building Momentum Across All Markets
Veradigm Announces Strategic Investment in Holmusk
Is This The End of Capitalism?
EXPOSED: The establishment plot to disenfranchise and impoverish millions of Americans…
SVB Securities Reaffirms Their Buy Rating on Allscripts (MDRX)
AllScripts Healthcare (MDRX) Q3 Earnings Top Estimates
Allscripts announces third quarter of 2022 results
Allscripts Healthcare Solutions, Inc. (MDRX)
Allscripts to Host Virtual Investor Day September 28th
See More Headlines
Receive MDRX Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Veradigm and its competitors with MarketBeat's FREE daily newsletter.

MDRX Company Calendar

Last Earnings
11/03/2022
Today
1/27/2023
Next Earnings (Confirmed)
2/23/2023
Fiscal Year End
12/31/2023

Industry, Sector and Symbol

Industry
Computer integrated systems design
Sub-Industry
Health Care Technology
Current Symbol
NASDAQ:MDRX
CUSIP
01988P10
Employees
8,000
Year Founded
1986

Price Target and Rating

Average Stock Price Forecast
$22.67
High Stock Price Forecast
$26.00
Low Stock Price Forecast
$17.00
Forecasted Upside/Downside
+26.8%
Consensus Rating
Moderate Buy
Rating Score (0-4)
2.57
Research Coverage
7 Analysts

Profitability

Net Income
$134.44 million
Pretax Margin
14.59%

Debt

Sales & Book Value

Annual Sales
$1.50 billion
Cash Flow
$2.73 per share
Book Value
$11.49 per share

Miscellaneous

Free Float
106,758,000
Market Cap
$1.95 billion
Optionable
Optionable
Beta
1.01

Social Links


Key Executives

  • Mr. Richard J. PoultonMr. Richard J. Poulton (Age 58)
    CEO & Director
    Comp: $2.45M
  • Ms. Tejal Vakharia (Age 49)
    Sr. VP of Marketing & Gov. Affairs, Gen. Counsel and Chief Compliance Counsel
    Comp: $1.04M
  • Mr. Thomas J. Langan (Age 57)
    Pres & CCO
  • Ms. Leah Jones (Age 50)
    Chief Financial Officer
  • Mr. Joseph R. Rostock (Age 60)
    Sr. VP of Devel. & CTO
  • Jenny Gelinas
    VP of Investor Relations
  • Mr. Richard Elmore
    Sr. VP of Corp. Devel. & Strategy
  • Ms. Rebecca Whaley
    VP of Marketing
  • Ms. Lisa Hammond C.P.C. (Age 50)
    Sr. VP & Chief HR Officer
  • Mr. Paul Lewis
    Sr. VP of Sales & Services and Acting Gen. Mang.













MDRX Stock - Frequently Asked Questions

Should I buy or sell Veradigm stock right now?

7 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Veradigm in the last year. There are currently 1 sell rating, 1 hold rating and 5 buy ratings for the stock. The consensus among Wall Street analysts is that investors should "buy" MDRX shares.
View MDRX analyst ratings
or view top-rated stocks.

What is Veradigm's stock price forecast for 2023?

7 equities research analysts have issued 12-month target prices for Veradigm's shares. Their MDRX share price forecasts range from $17.00 to $26.00. On average, they expect the company's stock price to reach $22.67 in the next twelve months. This suggests a possible upside of 26.8% from the stock's current price.
View analysts price targets for MDRX
or view top-rated stocks among Wall Street analysts.

How have MDRX shares performed in 2023?

Veradigm's stock was trading at $17.64 at the beginning of 2023. Since then, MDRX shares have increased by 1.3% and is now trading at $17.87.
View the best growth stocks for 2023 here
.

Are investors shorting Veradigm?

Veradigm saw a increase in short interest during the month of January. As of January 15th, there was short interest totaling 10,740,000 shares, an increase of 21.6% from the December 31st total of 8,830,000 shares. Based on an average trading volume of 1,300,000 shares, the short-interest ratio is currently 8.3 days. Currently, 10.1% of the company's shares are sold short.
View Veradigm's Short Interest
.

When is Veradigm's next earnings date?

The company is scheduled to release its next quarterly earnings announcement on Thursday, February 23rd 2023.
View our MDRX earnings forecast
.

How can I listen to Veradigm's earnings call?

Veradigm will be holding an earnings conference call on Thursday, February 23rd at 4:30 PM Eastern. Interested parties can register for or listen to the call using this link.

How were Veradigm's earnings last quarter?

Veradigm Inc. (NASDAQ:MDRX) posted its quarterly earnings results on Thursday, November, 3rd. The software maker reported $0.20 EPS for the quarter, beating analysts' consensus estimates of $0.15 by $0.05. The software maker had revenue of $151.90 million for the quarter, compared to analyst estimates of $152.79 million. Veradigm had a trailing twelve-month return on equity of 10.74% and a net margin of 7.25%. The business's quarterly revenue was up 5.0% compared to the same quarter last year. During the same quarter in the previous year, the company posted $0.21 EPS.

How will Veradigm's stock buyback program work?

Veradigm announced that its board has approved a share repurchase program on Wednesday, May 26th 2021, which authorizes the company to buyback $350,000,000.00 in shares, according to EventVestor. This buyback authorization authorizes the company to purchase up to 14% of its shares through open market purchases. Shares buyback programs are often an indication that the company's leadership believes its shares are undervalued.

What guidance has Veradigm issued on next quarter's earnings?

Veradigm updated its FY 2023 earnings guidance on Wednesday, January, 11th. The company provided EPS guidance of $0.90-$1.00 for the period, compared to the consensus EPS estimate of $0.95. The company issued revenue guidance of $640.00 million-$660.00 million, compared to the consensus revenue estimate of $656.84 million.

What is Paul Black's approval rating as Veradigm's CEO?

796 employees have rated Veradigm Chief Executive Officer Paul Black on Glassdoor.com. Paul Black has an approval rating of 65% among the company's employees.

What other stocks do shareholders of Veradigm own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Veradigm investors own include Advanced Micro Devices (AMD), Netflix (NFLX), Energy Transfer (ET), CVS Health (CVS), Ford Motor (F), Himax Technologies (HIMX), Intel (INTC), OPKO Health (OPK), Tesla (TSLA) and Activision Blizzard (ATVI).

What is Veradigm's stock symbol?

Veradigm trades on the NASDAQ under the ticker symbol "MDRX."

Who are Veradigm's major shareholders?

Veradigm's stock is owned by a number of institutional and retail investors. Top institutional investors include Peregrine Capital Management LLC (0.55%), Allspring Global Investments Holdings LLC (0.26%), Comerica Bank (0.08%), State of Alaska Department of Revenue (0.07%), Yousif Capital Management LLC (0.07%) and SummerHaven Investment Management LLC (0.05%). Insiders that own company stock include Brian Farley, David B Stevens, Dennis Olis, Elaina Shekhter, Elizabeth Ann Altman, Greg Garrison, Leah Jones, Lisa Khorey, Michael Klayko, Paul Black, Richard J Poulton, Tejal Vakharia and Thomas Langan.
View institutional ownership trends
.

How do I buy shares of Veradigm?

Shares of MDRX stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is Veradigm's stock price today?

One share of MDRX stock can currently be purchased for approximately $17.87.

How much money does Veradigm make?

Veradigm (NASDAQ:MDRX) has a market capitalization of $1.95 billion and generates $1.50 billion in revenue each year. The software maker earns $134.44 million in net income (profit) each year or $0.43 on an earnings per share basis.

How many employees does Veradigm have?

The company employs 8,000 workers across the globe.

Does Veradigm have any subsidiaries?
The following companies are subsidiares of Veradigm: HealthGrid, Practice Fusion, and ZappRx.
Read More
How can I contact Veradigm?

Veradigm's mailing address is 222 MERCHANDISE MART PLAZA SUITE 2024, CHICAGO IL, 60654. The official website for the company is www.allscripts.com. The software maker can be reached via phone at (800) 334-8534, via email at stephen.shulstein@allscripts.com, or via fax at 313-322-9600.

This page (NASDAQ:MDRX) was last updated on 1/27/2023 by MarketBeat.com Staff